{"Clinical Trial ID": "NCT01519700", "Intervention": ["INTERVENTION 1:", "EP2006 + EP2006 & Neupogen", "All subjects randomized to either EP2006 in Cycle 1", "INTERVENTION 2:", "\u2022 Neupogen + Neupogen & EP2006", "All subjects randomized to receive Neupogen in cycle 1"], "Eligibility": ["Incorporation criteria:", "Patients with histologically proven breast cancer eligible for neoadjuvant or adjuvant myelosuppressive chemotherapy", "Women 18 years of age", "Estimated life expectancy of more than six months", "- Exclusion criteria:", "- Prior or concomitant malignancy, except invasive non-melanoma skin cancer, in situ cervix carcinoma or other solid tumour treated curatively, and without evidence of recurrence for at least 10 years prior to entry into the study.", "Any serious illness or condition that may adversely affect safety, compliance, response to and assessment of products under investigation, e.g.:", "Other inclusion/exclusion criteria defined by the Protocol may apply."], "Results": ["Performance measures:", "Average duration of grade 4 neutropenia during cycle 1 of chemotherapy", "Average duration of severe neutropenia, defined as the average number of consecutive days with grade 4 neutropenia (ANC less than 0.5*10^9 cells/L)", "Time limit: 21 days (Cycle 1 of chemotherapy treatment)", "Results 1:", "Title of the arm/group: EP2006 + EP2006 & Neupogen", "Description of the arm/group: All subjects randomized to receive either EP2006 in Cycle 1", "Total number of participants analysed: 101", "Average (standard deviation)", "Unit of measurement: Days 1.17 (1.11)", "Results 2:", "Title of the arm/group: Neupogen + Neupogen & EP2006", "Description of the arm/group: All subjects randomized to receive Neupogen in Cycle 1", "Total number of participants analysed: 103", "Average (standard deviation)", "Unit of measurement: Days 1.2 (1.02)"], "Adverse Events": ["Undesirable Events 1:", "Total: 6/53 (11.32 per cent)", "Neutropenia3/53 (5.66%)", "Anemia/53 (0.00 %)", "Leucopenia1/53 (1.89%)", "Diarrhoea/53 (0.00 %)", "Embolie1/53 (1.89%)", "Adverse Events 2:", "Total: 4/54 (7.41%)", "Febrile Neutropenia4/54 (7.41%)", "Anemia/54 (0.00 %)", "- Leucopenia0/54 (0.00 %)", "Diarrhoea/54 (0.00 %)", "- Embolie0/54 (0.00 %)"]}